Passa al contenuto
Merck
Tutte le immagini(3)

Documenti

G6423

Sigma-Aldrich

Gemcitabine hydrochloride

≥98% (HPLC), powder, antitumor agent

Sinonimo/i:

2′-Deoxy-2′,2′-difluorocytidine; dFdC, Gemzar (Lilly), LY-188011, dFdC, dFdCyd

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(3)

About This Item

Formula empirica (notazione di Hill):
C9H11F2N3O4 · HCl
Numero CAS:
122111-03-9
Peso molecolare:
299.66
Numero MDL:
MFCD01735988
Codice UNSPSC:
12352200
ID PubChem:
329799951
NACRES:
NA.77

product name

Gemcitabine hydrochloride, ≥98% (HPLC)

Saggio

≥98% (HPLC)

Forma fisica

powder

Condizioni di stoccaggio

desiccated
protect from light

Solubilità

H2O: ≥10 mg/mL

Ideatore

Eli Lilly

Temperatura di conservazione

room temp

Stringa SMILE

Cl.NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)C2(F)F

InChI

1S/C9H11F2N3O4.ClH/c10-9(11)6(16)4(3-15)18-7(9)14-2-1-5(12)13-8(14)17;/h1-2,4,6-7,15-16H,3H2,(H2,12,13,17);1H/t4-,6-,7-;/m1./s1
OKKDEIYWILRZIA-OSZBKLCCSA-N

Informazioni sul gene

human ... POLA1(5422) , POLA2(23649) , POLD1(5424) , POLD2(5425) , POLD3(10714) , POLD4(57804) , POLE(5426) , POLE2(5427) , POLE3(54107) , PRIM1(5557) , PRIM2(5558) , RRM1(6240) , RRM2(6241) , RRM2B(50484)

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Descrizione generale

Gemcitabineis a pyrimidine nucleoside analog of deoxycytidine. It exhibits anticancereffects against various cancers.

Applicazioni

Gemcitabinehydrochloride has been used as a chemotherapeutic agent to study its effects onthe human pancreatic adenocarcinoma cell lineIt has been used as a chemotherapeutic to study its resistance inpancreatic stellate cells (PSCs)It has also been used to study its effects on patient-derivedxenograft (PDX) organoids.

Azioni biochim/fisiol

Gemcitabine is a widely used antitumor agents in both clinics and research labs. It is an antineoplastic agent and antimetabolite.

Caratteristiche e vantaggi

This compound is a featured product for Apoptosis research. Click here to discover more featured Apoptosis products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound was developed by Eli Lilly. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Pittogrammi

Health hazard
GHS08

Avvertenze

Danger

Indicazioni di pericolo

H360

Classi di pericolo

Repr. 1B

Codice della classe di stoccaggio

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Certificati d'analisi (COA)

Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 7

1 of 7

Capecitabine ≥98% (HPLC)

Sigma-Aldrich

SML0653

Capecitabine

Carboplatin

Sigma-Aldrich

C2538

Carboplatin

Irinotecan hydrochloride topoisomerase inhibitor

Sigma-Aldrich

I1406

Irinotecan hydrochloride

5-Fluorouracil Potent antitumor agent.

Sigma-Aldrich

343922

5-Fluorouracil

Doxorubicina 98.0-102.0% (HPLC)

Sigma-Aldrich

D1515

Doxorubicina

Oxaliplatin powder

Sigma-Aldrich

O9512

Oxaliplatin

Docetaxel purum, ≥97.0% (HPLC)

Sigma-Aldrich

01885

Docetaxel

Yuan Chi et al.
Frontiers in oncology, 11, 671082-671082 (2021-12-07)
Pancreatic cancer is associated with poor prognosis and dismal survival rates. This study aims to investigate roles of lncRNA UCA1-loaded exosomes secreted by pancreatic stellate cells (PSCs) in Gemcitabine (Gem) resistance of pancreatic cancer under hypoxia, which involves the methylation
M Barton-Burke
Cancer nursing, 22(2), 176-183 (1999-04-27)
There have been exciting new developments in anticancer therapy over the past few years. One such therapy uses gemcitabine (GemzarR), an antimetabolite approved in 1996 by the Food and Drug Administration (FDA) for first-line treatment of locally advanced (nonresectable stage
Abdullah Shopit et al.
Phytomedicine : international journal of phytotherapy and phytopharmacology, 91, 153711-153711 (2021-08-28)
Gemcitabine (GCB) is a first-line chemotherapeutic drug for pancreatic cancer (PCa). However, the resistance begins developing within weeks of chemotherapy. SPINK1 overexpression enhances resistance to chemotherapy. In a recent study, our laboratory established that the oleanolic acid (OA) derivative, K73-03
Isabel Romero-Calvo et al.
Molecular cancer research : MCR, 17(1), 70-83 (2018-09-02)
Patient-derived pancreatic ductal adenocarcinoma (PDAC) organoid systems show great promise for understanding the biological underpinnings of disease and advancing therapeutic precision medicine. Despite the increased use of organoids, the fidelity of molecular features, genetic heterogeneity, and drug response to the
Erez Hasnis et al.
Neoplasia (New York, N.Y.), 16(6), 501-510 (2014-06-25)
Weekly gemcitabine therapy is the major treatment offered for patients with pancreatic adenocarcinoma cancer; however, relative resistance of tumor cells to chemotherapy, rapid regrowth, and metastasis are the main causes of death within a year. Recently, the daily continuous administration
Visualizza tutti i documenti correlati

Articoli

Discover Bioactive Small Molecules for Cell Cycle

Cell cycle phases (G1, S, G2, M) regulate cell growth, DNA replication, and division in proliferating cells.

Bioactive Molecules for Apoptosis

Apoptosis regulation involves multiple pathways and molecules for cellular homeostasis.

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.